|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, immunisation with the NP-MN system induced a tumour-specific cellular immune response, and inhibited the growth of TRAMP-C1 prostate tumours in both prophylactic and therapeutic challenge models in vivo.
|
31299353 |
2019 |
|
Prostatic Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we identify the extracelular matrix protein mindin in the secretome of prostate adenocarcinoma cells and show that mindin overexpression in human and mouse TRAMP-C1-induced prostate tumors correlates with upregulated levels of bone-related genes in the tumorigenic prostate tissues.
|
31168562 |
2019 |
|
Prostatic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Prevention of Prostate Tumor Development by Stimulation of Antitumor Immunity Using a Standardized Herbal Extract (Deep Immune®) in TRAMP Mice.
|
29861778 |
2018 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, Src<sup>pY416</sup> and c-Src are both expressed in Exo isolated from the plasma of prostate tumor-bearing TRAMP mice, and those same mice have higher levels of exosomal c-Src than their wild-type counterparts.
|
27232975 |
2017 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In TRAMP transgenic mice, an in vivo model of prostate adenocarcinoma (AC), oral administration of alkaline water was devoid of unwanted side effects, and when started from an early age was as effective as NaHCO<sub>3</sub> in significantly delaying tumour progression, while when started when prostate tumours were already present, a nonstatistically significant trend in the same direction was detected.
|
28095711 |
2017 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.
|
27634876 |
2016 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HGFL-/- TRAMP+ mice developed significantly smaller prostate tumors compared to controls.
|
24980820 |
2014 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aimed to evaluate whether co-expression of interleukin-3 (IL-3) could enhance the anti-tumor activity of HSV-sr39tk/GCV prodrug gene therapy using a murine TRAMP-C1 prostate tumor model.
|
23441198 |
2013 |
|
Prostatic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CD11b(+) S100A9 expressing cells were not observed in normal prostate tissue from control C57BL/6 mice but were readily detected in TRAMP prostate tumors.
|
22470535 |
2012 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, TK-/- TRAMP+ prostate tumors exhibited decreased tumor vascularization relative to TK+/+ TRAMP+ prostate tumors, which correlated with reduced levels of the angiogenic molecules vascular endothelial growth factor and CXCL2.
|
21625214 |
2011 |
|
Prostatic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Formation of NE prostate tumors in the TRAMP mouse model was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1alpha availability.
|
20609350 |
2010 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interestingly, knockdown of both epithelial and stromal AR in ind-ARKO-TRAMP mice at earlier stages resulted in smaller primary prostate tumors with lower proliferation rates, and knockout of AR in pes-ARKO-TRAMP mice resulted in larger primary prostate tumors with higher proliferation rates.
|
18723670 |
2008 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Initial studies described herein comparing the efficacy of three different oncolytic HSVs (G207, G47Delta, and NV1023) to inhibit the growth of the poorly immunogenic TRAMP-C2 mouse prostate tumors demonstrated that NV1023 was most effective in treating established tumors.
|
16179929 |
2006 |
|
Prostatic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of an adenovirally-delivered luciferase reporter gene in prostate tumor cells in bigenic mice (PSA/hCAR + TRAMP) was enhanced compared to the level in tumor cells lacking the PSA/hCAR transgene.
|
15761871 |
2005 |
|
Prostatic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice.
|
14751836 |
2003 |